Exhibit 10.13

COLLABORATION AGREEMENT

THIS COLLABORATION AGREEMENT (the "Agreement") is  {E1 entered}  into as of  November 2, 2012  (the "Effective  Date  ") by and between BIOCEPT, INC., a California corporation  having  an address of 5810 Nancy Ridge Drive, Suite 150, San Diego, CA 92121 ("Biocept"), and LIFE TECHNOLOGIES  CORPORATION, a Delaware corporation  having  an address of 5791 Van Allen Way, Carlsbad, California 92008 ("Life Technologies"). WHEREAS, Life Technologies, through its Medical Sciences Division, is  {E2 engaged}  in the {E152 development} and {E153 commercialization} of diagnostic systems, tests and laboratory {E154 services},  {E3 including}  in oncology;

WHEREAS, Biocept has  {E4 developed}  expertise and proprietary technology in {E155 enrichment}, {E156 extraction} and {E157 analysis} of  {E5 circulating}  tumor cells (CTCs) for {E158 use} in laboratory  {E6 developed}  tests  {E7 used}  for the non-invasive and early stage {E159 detection} and {E160 characterization} of primary, metastatic or recurrent cancers; and

WHEREAS, Life Technologies and Biocept desire to  {E8 collaborate}  so that Biocept will  {E9 develop}  and  {E10 commercialize}  one or more Tests, as  {E11 defined}  herein, for Non-Small Cell Lung Cancer (NSCLC),  {E12 using}  their respective technologies and expertise, on the terms and subject to the conditions set forth herein. Life Technologies and Biocept will both  {E185 promote}  the test and  {E14 perform}  different components of the test, and Life Technologies will  {E15 provide}  test results in the form of {E161 reports} to physicians. NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants  {E16 contained}  herein, and  {E17 intending}  to be legally  {E18 bound}  , the parties hereby  {E19 agree}  as  follows  :   1. DEFINITIONS

1.1 "Affiliate" shall mean any company or entity controlled by, controlling, or under common control with a party hereto and shall include any company more than 50% of whose voting stock or participating profit interest is owned or controlled, directly or indirectly, by a party, and any company which owns or controls, directly or indirectly, more than 50% of the voting stock of a party. 1.2 "Assay" shall mean Biocept's OncoCEE-LUâ¢ (and OncoCEE-LUâ¢ with Mutation {E162 Analysis}) laboratory developed assay for {E163 characterization} and {E164 profiling} of CTCs from NSCLC patients, which shall incorporate, as Phase 1, CTC {E165 enumeration} by cytokeratin and CD45 (and CEE-Enhancedâ¢ when available), EML4/Alk1 {E166 fusions} and EGFR {E167 amplification} by {E169 fluorescence} in situ {E168 hybridization} (determined by Biocept); and as Phase 2, the additional {E170 detection} of mutations for relevant genes, e.g., K-RAS, EGFR and B-RAF, as agreed by the parties, on captured CTCs and/or cell-free circulating DNA, as agreed by the parties, and employing technologies that potentially may include Biocept's Selector technology, and any {E171 improvements} or {E172 enhancements} thereto, exclusive of new analytes (which are discussed in Section 3.5(f) under Collaboration Assays) or applications to primary screening. 1.3 "Biocept Trademarks" shall mean Biocept, Inc., "OncoCEE-LU ", "OncoCEEâ¢", "CEE-Sure ", CEE- Enhancedâ¢", and/or such other trademarks and trade names owned or licensed, and used, by Biocept and/or its Affiliates in the Territory to identify the Tests, in each case, whether or not registered. 1.4 "Life Technologies Trademarks," shall mean Life Technologies , Life Technologies Medical Sciences and/or such other trademarks and trade names owned or licensed and used by Life Technologies to identify the Tests, in each case, whether or not registered. 1.5 "CLIA" shall mean the Clinical Laboratory Improvement Amendments of  1988 , as it may be amended from time to time. 1.6 "{E176 Collaboration}" shall have the meaning provided Section 3.1. 1.7 "Collaboration Assay(s)" shall have the meaning provided in Section 3.5(e). 1.8 "CPT Code" shall mean the American Medical Association's ("AMA") " Current  Procedural Terminology" as published in the AMA's CPT Process Manual, Fourth Edition and any such future editions, for procedures used in {E174 performance} of the Assay, and amounts reimbursed by Medicare for such procedures for location 99, as {E149 modified}  annually . 1.9 "Designated Executive Officer" shall mean the executive officers of each party designated in writing be each party as being responsible for resolving {E175 disputes} related to the {E176 Collaboration}, which shall initially be David Hale on behalf of Biocept and Ronnie Andrews on behalf of Life Technologies. 1.10 "FDA" shall mean the United States Food and Drug Administration, or any successor federal agency thereto. 1.11 "HIPAA" shall mean, collectively, the Health Insurance Portability and Accountability Act of  1996 , as amended, and all regulations promulgated thereunder at 45 C.F.R. parts 160 through 164, and the Health Information Technology for Economic and Clinical Health Act of  2009  and related regulations and guidelines. 1.12 "Intellectual Property Rights" means all  now  or hereafter existing patents, patent applications, copyrights, trademarks (including service marks), trade secrets, know-how, mask work rights and design rights, whether registered or unregistered, and all rights or forms of protection of a similar nature having equivalent or similar effect to any of the foregoing, which may subsist anywhere in the world. 1.13 "{E177 Launch}" shall mean formal commercial availability and {E178 offering} to physicians of a Test, as mutually agreed upon by the parties. 1.14 "Laws" shall mean all federal, state and local laws and regulations that apply to this Agreement including, without limitation, (i) the Bayh-Dole Act (ii) the

2

TM TM

TM

Federal Food, Drug, and Cosmetic Act (21 U.S.C Â§ 321 et seq.) (iii) the federal Anti-kickback Statute (42 U.S.C. Â§ 1320a- 7b(b)) (iv) the Stark Law (42 U.S.C. Â§ 1395nn) (v) the Anti-Inducement Law (42 U.S.C. Â§ 1320a-7a(a)(5)) (vi) the civil False Claims Act (31 U.S.C. Â§Â§ 3729 et seq.) (vii) the administrative False Claims Law (42 U.S.C. Â§ 1320a-7b(a)) (viii) the Health Insurance Portability and Accountability Act of  1996  (42 U.S.C. Â§ 1320d et seq.), (ix) the exclusion laws (x) SSA Â§  1128  (42 U.S.C. Â§ 1320a-7) (xi) Medicare (Title XVIII of the Social Security Act), (xii) Medicaid (Title XIX of the Social Security Act); (xiii) the Clinical Laboratory Improvements Act of  1988  (CLIA); and (xiv) data security, protection and privacy laws in the applicable jurisdictions. 1.15 "Professional Component" shall mean the {E237 performance} of the professional component of the steps of the Assay, which is the {E237 interpretation} of results (generated in the Technical Component) of an Assay by a pathologist, and is covered by CPT codes from the Professional Fee Schedule with the modifier "26". 1.16 "Technical Component" shall mean the {E181 performance} of the technical component of the steps of the Assay, which is the physical {E181 performance} of the Assay procedure up to the interpretation of results, and is covered by CPT codes from the Professional Fee Schedule without the modifier "26", and typically with a modifier "TC". 1.17 " Term  " shall have the meaning provided in Section 11.1. 1.18 "Test(s)" shall mean the Assay, which is a laboratory developed test, and/or any Collaboration Assay which is added to this Agreement pursuant to Section 3.5(e), performed as a clinical reference laboratory test. 1.19 "Territory" shall mean the United States of America, and other countries of the world, contingent in the latter case on the parties agreeing in writing on an appropriate strategy to access them in accordance with Section 3.2. 1.20 "Third Party(ies)" shall mean any entity other than Biocept or Life Technologies or an Affiliate of Biocept or Life Technologies. 2. APPOINTMENT; LICENSES

2.1 Appointment. Upon the terms and conditions set forth in this Agreement, Biocept hereby  {E20 grants}  Life Technologies during the  Term  the non-exclusive right, as further  {E21 defined}  in Section 2.3, to  {E22 promote}  the Tests in the Territory and to  {E23 perform}  the Professional Component of the Tests  {E93 sold}  by the parties in the Territory, in accordance with the terms of this Agreement. 2.2 Trademark Licenses. The parties hereby  {E25 grant}  to each other non-exclusive, fully- {E26 paid}  , royalty-free licenses to  {E27 utilize}  the other party's trademarks, as  follows  :

(a) Biocept Trademarks. To  {E28 facilitate}  the {E185 promotion} and {E186 performance} of Tests, during the  Term  Biocept hereby  {E29 grants}  Life Technologies a non-exclusive, royalty-free, non-transferable license to  {E184 use}  the Biocept Trademarks solely for

3

{E184 use} in connection with the {E185 promotion} and {E186 performance} of the Tests in the Territory. All materials  {E31 associated}  with the Tests and  {E32 used}  by Life Technologies in connection with the {E185 promotion} of the Tests,  {E33 including}  web- based  , shall be  {E150 co   -   branded}  with such Biocept Trademarks as  {E34 approved}  by Biocept prior to {E188 distribution}. All {E190 use} of Biocept Trademarks by Life Technologies hereunder ( {E35 including}  all goodwill  {E36 arising}  as a result of such {E190 use}) shall  {E37 inure}  to the benefit of Biocept, and these rights, whether registered or not  {E38 registered}  , at all times shall  {E39 remain}  the sole property of Biocept.  {E40 Biocept}  shall  {E41 provide}  Life Technologies with copies of the Biocept Trademarks in an appropriate form for the {E191 uses}  {E42 contemplated}  in this Agreement. Life Technologies shall  {E43 provide}  Biocept with samples of all  {E45 proposed}  {E193 use} of the Biocept Trademarks in advance of such  {E45 proposed}  {E193 use} and Biocept shall have the right to  {E46 approve}  the appearance and {E194 placement} of Biocept Trademarks by Life Technologies for the purpose of  {E47 protecting}  and  {E48 maintaining}  the standards of quality  {E49 maintained}  by Biocept for products  {E50 sold}  under the Biocept Trademarks and for {E195 use} of the Biocept Trademarks. If Biocept at any time  {E51 finds}  that Life Technologies is not in compliance with this Section, then Biocept may  {E52 notify}  Life Technologies in writing of such deficiencies, and if Life Technologies  {E53 fails}  to  {E54 correct}  such deficiencies within thirty (30)  days  after {E196 receipt} of such notice, Biocept may, at its {E197 election} and in addition to any other remedies,  {E55 terminate}  the license  {E56 granted}  to Life Technologies with respect to the Biocept Trademarks. Life Technologies shall  {E57 display}  the â¢ or   symbol, as  {E58 directed}  by Biocept, in connection with Life Technologies' {E198 use} of the Biocept Trademarks. (b) Life Technologies Trademarks. To  {E59 facilitate}  the {E185 promotion} and {E186 performance} of Tests, during the  Term  Life Technologies hereby  {E60 grants}  Biocept a non-exclusive, royalty-free, non-transferable license to  {E201 use}  the Life Technologies Trademarks solely for {E201 use} in connection with the {E185 promotion} and {E186 performance} of the Tests in the Territory. Materials  {E62 associated}  with the Tests and  {E63 used}  by Biocept in connection with the {E185 promotion} of Tests,  {E64 including}  web- based  materials, may be  {E151 co   -   branded}  with such Life Technologies Trademarks as  {E65 approved}  by the parties prior to {E205 distribution}. All {E207 use} of Life Technologies Trademarks by Biocept hereunder  {E66 including}  all goodwill  {E67 arising}  as a result of such {E207 use}) shall  {E68 inure}  to the benefit of Life Technologies, and these rights, whether registered or not  {E69 registered}  , at all times shall  {E70 remain}  the sole property of Life Technologies. Life Technologies shall  {E71 provide}  Biocept with copies of the Life Technologies Trademarks in an appropriate form for the {E208 uses}  {E72 contemplated}  in this Agreement. Biocept shall  {E73 provide}  Life Technologies with samples of all  {E75 proposed}  {E210 use} of the Life Technologies Trademarks in advance of such  {E75 proposed}  {E210 use} and Life Technologies shall have the right to  {E76 approve}  the appearance and {E211 placement} of Life Technologies Trademarks by Biocept for the purpose of  {E77 protecting}  and  {E78 maintaining}  the standards of quality  {E79 maintained}  by Life Technologies for products  {E80 sold}  under the Life Technologies Trademarks and for {E212 use} of the Life Technologies Trademarks. If Life Technologies at any time  {E81 finds}  that Biocept is not in compliance with this Section, then Life Technologies may  {E82 notify}  Biocept in writing of such deficiencies, and if Biocept  {E83 fails}  to  {E84 correct}  such deficiencies within thirty (30)  days  after {E213 receipt} of such notice, Life Technologies may, at its {E214 election} and in addition to any other remedies,  {E85 terminate}  the license  {E60 granted}  to Biocept with respect to the Life Technologies Trademarks. Biocept shall  {E87 display}  the â¢ or   symbol, as  {E88 directed}  by Life Technologies, in connection with Biocept's {E215 use} of the Life Technologies Trademarks. 4

Â®

Â®

2.3 Exclusivity. During the  Term  , the parties will  {E185 promote}  and  {E186 perform}  Tests for the clinical testing market on a non- exclusive basis in the Territory, except as otherwise  {E91 provided}  for below. Biocept will have sole responsibility for  {E92 performing}  the Technical Component of all Tests  {E93 sold}  by the parties, until and unless Life Technologies  {E94 obtains}  the right from Biocept to independently  {E95 develop}  its own Tests in accordance with all applicable FDA regulatory requirements, as  {E96 provided}  for in Section 7.1. Life Technologies will be  {E97 authorized}  to  {E23 perform}  the Professional Component of all Tests  {E93 sold}  by the parties, although Biocept may  {E100 engage}  other groups in promotion, marketing and performance arrangements for the Tests, at the discretion of Biocept. Biocept shall  {E101 provide}  thirty (30)  days   {E102 written}  notice to Life Technologies before  {E103 entering}  into any such promotion, marketing and performance arrangement. 3. COLLABORATION

3.1 Purpose. During the  Term  , the parties  {E104 agree}  to  {E105 cooperate}  and  {E106 collaborate}  to  {E107 develop}  ,  {E185 promote}  and  {E216 commercialize}  the Tests for the clinical testing market in the Territory and in accordance with the terms of this Agreement (the "Collaboration"). The principal objective of the parties hereunder is to  {E110 maximize}  the {E216 commercialization} of the Tests in the Territory. The parties shall  {E111 deploy}  each of their respective sales forces in accordance with the terms of this Agreement in an effort to  {E185 promote}  the Tests in the Territory in the manner as  {E113 agreed}  to by the parties, under the direction of the Joint Steering Committee. 3.2 Commercialization of Tests Outside the USA. At any time for up to two (2)  years  after the Effective  Date  , should Life Technologies desire to  {E114 offer}  for {E235 sale} any Test outside the USA, it shall first  {E115 discuss}  with Biocept an appropriate strategy and plan for such {E236 effort}. Such strategy and plan may  {E116 involve}  the {E219 development} of, and  {E117 obtaining}  all applicable regulatory authorizations for, an in vitro diagnostic kit, instruments or similar systems, in {E220 collaboration} with Biocept (with funding {E221 support}, and more fully  {E118 described}  in Section 7.2), such strategy and plan to be  {E121 reduced}  to writing and  {E120 approved}  by the parties. If such  {E121 written}  plan is not  {E122 approved}  by the parties within two (2)  years  of the Effective  Date  , the Territory shall  {E123 revert}  to only the USA, unless otherwise  {E124 agreed}  to by the parties. 3.3 Life Technologies Responsibilities. Life Technologies shall  {E125 use}  commercially reasonable {E222 efforts} to  {E185 promote}  the Tests in the Territory, in accordance with Section 3.2,  {E127 using}  sales channels and methods, and  {E128 adhering}  to substantially similar standards that it generally  {E129 employs}  with respect to its laboratory  {E130 developed}  tests. Without  {E131 limiting}  the foregoing, Life Technologies' responsibilities with respect to {E223 marketing} and {E185 promotion} of the Tests in the Territory during the  Term  shall  {E132 include}  the  following  :

(a) Life Technologies Customers. Life Technologies shall  {E133 use}  commercially reasonable {E225 efforts} to  {E134 promote}  the Tests to the appropriate healthcare professionals. 5

(b) Test Performance. Life Technologies shall have the responsibility, subject to its capacity to  {E135 support}  in its reasonable discretion (of which capacity Life Technologies shall  {E136 notify}  Biocept in  {E137 writing}  at least sixty (60)  days  before {E226 launch} of the Assay, and  {E138 use}  diligent {E227 efforts} to  {E139 notify}  Biocept at least thirty (30)  days  before {E228 discovery} of any {E229 decreases} or {E230 increases} in such capacity), for  {E23 performing}  the Professional Component of the Assays  {E93 sold}  by either party in the Territory. In particular, the laboratory director of the Life Technologies CLIA laboratory will be responsible for  {E142 issuing}  and  {E143 signing}  off on the {E231 report}. (c) Sales, Marketing and Customer Service. (i) Life Technologies shall, at its sole expense and in accordance with Section 2.2,  {E144 develop}  and  {E145 deliver}  to customers marketing materials for the Tests. Life Technologies shall  {E146 use}  , as appropriate, Biocept's "OncoCEE-LU ", OncoCEEâ¢", "CEE-Enhancedâ¢" and "CEE-Sure" brand and the Biocept corporate name and logo, together with any Life Technologies  {E147 branding}  , as part of the marketing materials for the {E232 marketing} of the Tests and, where appropriate, in its other public {E233 presentations} and {E234 disclosures}  {E148 concerning}  the Assay or Tests.



#COLOR:E176=hsl(0, 100%, 80%)
#COLOR:E237=hsl(25, 100%, 80%)
#COLOR:E181=hsl(50, 100%, 80%)
#COLOR:E23=hsl(0, 100%, 70%)
#COLOR:E185=hsl(100, 100%, 80%)
#COLOR:E186=hsl(125, 100%, 80%)
#COLOR:E184=hsl(75, 100%, 80%)
#COLOR:E190=hsl(150, 100%, 80%)
#COLOR:E45=hsl(175, 100%, 80%)
#COLOR:E193=hsl(200, 100%, 80%)
#COLOR:E60=hsl(350, 100%, 80%)
#COLOR:E201=hsl(225, 100%, 80%)
#COLOR:E207=hsl(250, 100%, 80%)
#COLOR:E75=hsl(275, 100%, 80%)
#COLOR:E210=hsl(300, 100%, 80%)
#COLOR:E93=hsl(25, 100%, 70%)
#COLOR:E216=hsl(325, 100%, 80%)
#COLOR:E121=hsl(50, 100%, 70%)

#TOKENIZATION-TYPE:1

